Brief Report
Version 1
Preserved in Portico This version is not peer-reviewed
Yin-Yang Balance of ACE/ACE2 Pathways: The Rational for ACE2 Pathway Inhibitor Administration in SARS-CoV-2 Patients
Version 1
: Received: 19 March 2020 / Approved: 23 March 2020 / Online: 23 March 2020 (06:29:42 CET)
Version 2 : Received: 23 March 2020 / Approved: 24 March 2020 / Online: 24 March 2020 (06:47:18 CET)
Version 3 : Received: 5 May 2020 / Approved: 6 May 2020 / Online: 6 May 2020 (04:40:25 CEST)
Version 2 : Received: 23 March 2020 / Approved: 24 March 2020 / Online: 24 March 2020 (06:47:18 CET)
Version 3 : Received: 5 May 2020 / Approved: 6 May 2020 / Online: 6 May 2020 (04:40:25 CEST)
A peer-reviewed article of this Preprint also exists.
Zamai, L. The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients. Cells 2020, 9, 1704. Zamai, L. The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients. Cells 2020, 9, 1704.
Abstract
The article describes the rational for inhibition of the angiotensin-converting enzyme 2 (ACE2) pathways as specific targets in patients infected by SARS-CoV-2.
Supplementary and Associated Material
https://www.researchgate.net/project/Searching-for-a-therapy-for-SARS-CoV-2: researchgate page
Keywords
Severe Acute Respiratory Syndrome Coronavirus-2; (soluble) ACE2; eosinophil; asthma; IL-10; IL-6; Lung fibrosis; Ang (1-7); hypoxia; infarction; hypertension
Subject
Medicine and Pharmacology, Pulmonary and Respiratory Medicine
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment